Trevi Therapeutics (TRVI) Q2 FY26 earnings call

Trevi Therapeutics achieved significant clinical milestones in Q2 FY26, initiating two key trials for chronic cough indications and maintaining a strong financial position with cash runway into 2030. The company is focused on executing its development plan for nalbuphine ER, aiming to be a first-in-class therapy in areas of high unmet need, particularly following a competitor's program termination in refractory chronic cough.